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Parkinson’s disease (PD) has been associated with the development of impulse control disorders (ICDs), possibly due to
overstimulation of the mesolimbic system by dopaminergic medication. Preliminary reports have suggested that deep brain
stimulation (DBS), a neurosurgical procedure oﬀered to patients with treatment-resistant PD, aﬀects ICD in a twofold way.
Firstly, DBS allows a decrease in dopaminergic medication and hence causes an improvement in ICDs. Secondly, some studies
have proposed that speciﬁc ICDs may develop after DBS. This paper addresses the eﬀects of DBS on ICDs in patients with PD.
A literature search identiﬁed four original studies examining a total of 182 patients for ICDs and nine case reports of 39 patients
that underwent DBS and developed ICDs at some point. Data analysis from the original studies did not identify a signiﬁcant
diﬀerence in ICDs between patients receiving dopaminergic medication and patients on DBS, whilst the case reports showed that
56% of patients undergoing DBS had poor outcome with regards to ICDs. We discuss these ambivalent ﬁndings in the light of
proposed pathogenetic mechanisms. Longitudinal, prospective studies with larger number of patients are required in order to
fully understand the role of DBS on ICDs in patients with PD.
1.Introduction
Parkinson’s disease (PD) is increasingly recognized as a
neurodegenerative condition characterized by motor dys-
function and both physiological and psychological distur-
bances [1]. Although PD has been classically associated
with psychiatric comorbidities such as dementia [2]a n d
psychosis [3], recent studies have shown that patients with
PD can develop a variety of behavioral problems associated
with impulse dyscontrol, including pathological gambling,
hypersexuality, punding (repetitive purposeless motor acts
not distressing to the patient), and compulsive shopping
and eating [4]. These pathological behaviors are currently
classiﬁed as impulse control disorders (ICDs) and exert
negativeconsequencesintermsofthepatients’health-related
quality of life, mainly because of the interference with their
social functioning [5]. The aetiopathogenesis of ICDs in
patients with PD is not completely understood, but previous
studies showed that dopamine replacement therapy can
lead to the development of ICDs due to overstimulation of
the mesolimbic dopaminergic system [6] which modulates
behavioral responses to reward, motivation, and reinforce-
ment. A recent large cross-sectional study has shown that up
to 13.6% of patients with treated idiopathic PD may suﬀer
from ICDs [7], with hypersexuality, pathological gambling,
and compulsive shopping being the most common ones.
Levodopa use, younger age of onset of PD, and unmarried
status were associated with the development of ICDs. Other
predictive factors included being male, history of alcohol
abuse, and novelty seeking or impulsive personality traits
[8]. Finally, it has been consistently found that patients using
dopamine agonists are more likely to develop ICDs (6.3%)
than those using L-dopa (0.6%) [9].
In some patients, dopaminergic medication becomes
less eﬀective in treating motor symptoms. Deep brain
stimulation (DBS) is an eﬀective neurosurgical procedure2 Parkinson’s Disease
that can reduce motor symptoms in patients with treatment-
refractory PD (especially patients who developed levodopa-
induced dyskinesia), thus allowing decrease in their medica-
tion [10]. Consequently, DBS might have an indirect ben-
eﬁcial role in patients suﬀering from ICDs. However, DBS
may also have detrimental eﬀect on patients’ behaviours.
The most eﬀective target of DBS in PD is arguably the
subthalamic nucleus (STN), which plays a part in the fronto-
striato-thalamic-cortical loops mediating motor, cognitive,
and emotional functions [11], thus suggesting that DBS may
aﬀect patients’ behavior, in addition to motor performance.
Both case reports and clinical studies associating DBS
with the postoperative development of ICDs have provided
support to this hypothesis.
As the popularity of DBS increases and this neuro-
surgical procedure is oﬀered to patients suﬀering from
other treatment-resistant movement disorders commonly
associated with ICDs, such as Tourette syndrome [12], there
is a need of more conclusive results on its role in the devel-
opment of ICDs. This literature review assesses the current
evidence on the clinical implications of ICDs in patients with
PD who underwent DBS of the subthalamic nucleus.
2.LiteratureSearchMethodology
We performed a literature search across the databases
Medline, EMBASE, and PsycInfo to identify original studies
and case reports which examined the behavioral eﬀects of
DBS in patients with PD, with focus on ICDs, as deﬁned
in Chapter 5 of the ICD-10 classiﬁcation system [5]. We
used the search terms “Parkinson,” “deep brain stimulation”,
“impulse control disorder”, “impulsivity”, “hypersexuality”,
“pathological gambling”, “punding”, “compulsive shopping”,
“compulsive eating”, and “addiction”, and we limited our
search to papers published in English language.
3.OriginalStudies
Four original studies met our search criteria, examining a
totalof182patientsforICDs.Weselectivelyreviewedstudies
reporting patients with ICDs. As a result, due to publication
bias,theprevalenceofICDsafterDBScannotbeextrapolated
from the reviewed data.
Two studies (Funkiewiez et al. [13] and Contarino et
al. [14]) followed up patients with PD after DBS surgery,
in order to identify any changes in their behavioral proﬁle,
including impulse dyscontrol. The other two studies (H¨ albig
et al. [15] and Czernecki et al. [16]) performed a cross-
sectional evaluation comparing patients with PD-treated
DBS(PD+DBS)withthosetreatedwithdopaminergicmed-
ication (levodopa and/or dopamine agonists) (PD + DA). A
proportion of patients from the latter group remained on
medication postoperatively.
Table 1 summarizes the demographic and clinical char-
acteristics of the two groups of patients (PD + DBS and PD
+ DA) across the four studies. The PD + DBS group was
larger than the PD + DA group since only two of the four
studies included controls (PD + DA). The mean age of the
Table 1: Summary of demographic and clinical characteristics
of patients with Parkinson’s disease from four original studies
evaluating the eﬀects of deep brain stimulation on impulse control
disorders.
PD + DBS PD + DA
No. of patients 122 60
Gender: M/F/unknown 62/42/18 26/11/23
Mean age (years) 55 57
Mean disease duration (years) 14 10
Abbreviations.PD:Parkinson’sdisease;PD+DBS:patientswithParkinson’s
disease who underwent deep brain stimulation surgery (some remained on
medication postoperatively); PD + DA: patients with Parkinson’s disease
treated with dopaminergic medication.
patients was similar in both groups whereas disease duration
was higher in PD + DBS than in PD + DA, consistent with
the clinical practice of referring to neurosurgery patients
with longer disease duration who failed to respond to
medication. Motor evaluation of the patients in all studies
was performed using the Uniﬁed Parkinson’s Disease Rating
Scale III (UPDRS III). In the PD + DBS group, the UPDRS
III ranged from 10.1 (SD ± 2.4) (Czernecki et al.) to 20.8
(SD ± 12.1) (Contarino et al.), whereas in the PD + DA
group, the UPDRS III scores ranged from 16.3 (SD ± 10.6)
(H¨ albigetal.)to38.7(SD ±2.8)(Czerneckietal.).Exclusion
criteria included severe psychiatric conditions and cognitive
impairment measured by Minimental State Examination
(MMSE), possibly masking severe cases of ICDs.
Unfortunately, the methodology of each study diﬀered,
and hence no conclusive results can be drawn from the
patients as a group. Table 2 outlines the total number of
patients in each group (PD + DBS and PD + DA) and the
percentage of each group who developed ICDs.
H¨ albig et al. [15] identiﬁed a higher percentage of
patients with newly developed ICDs in the PD + DBS group
(19%) than in the PD + DA group (8%), but this was not
statistically signiﬁcant with P = .26 (Table 2). However, this
study identiﬁed a statistically signiﬁcant diﬀerence in overall
impulsivity (P = .04) between the two groups, with PD +
DBS reporting higher impulsivity scores (Table 3). Notably,
preoperative assessment of ICDs was not performed, so the
two groups may had been diﬀerent from the start. All of the
patients in the PD + DBS group were with stimulation “on”
at the time of the assessment and remained on dopaminergic
medication after surgery (56% on levodopa monotherapy,
44% on combined levodopa and dopamine agonist therapy)
with mean LEDD 682mg (SD ± 427mg). The PD + DA
group’s mean LEDD was 582mg (SD ± 480mg), with 38%
of the patients on levodopa monotherapy, 16% on dopamine
agonist monotherapy, and 46% on combined therapy.
Contarino et al. [14] and Funkiewiez et al. [13]r e p o r t e d
the development of ICDs in 18% (hypersexuality) and 2.5%
(aggressive impulsive behaviour) of their patients (Table 2).
Czernecki et al. [16] used methods described in Rolls et al.
[17]andBec haraetal.[18]tocomparetherewardsensitivity
(an indirect measure of impulsivity) of patients receiving
DBS (in both “on” and “oﬀ” conditions) with patientsParkinson’s Disease 3
Table 2: Development of impulse control disorders after deep brain stimulation or dopaminergic pharmacotherapy in patients with
Parkinson’s disease.
Study Type of study Number of patients in each study; n Number of patients developing ICDs; n (%)
PD + DBS PD + DA PD + DBS PD + DA
Halbig et al. Cross-sectional 16 37 3 (19%) 3 (8%)
Contarino et al. Longitudinal 11 0 2 (18%) n/a
Funkiewiez et al. Longitudinal 77 0 2 (2.5%) n/a
Czernecki et al. Cross-sectional 18 23 n/a n/a
Abbreviations. ICDs: impulse control disorders; PD: Parkinson’s disease; PD + DBS: patients with Parkinson’s disease who underwent deep brain stimulation
surgery; PD + DA: patients with Parkinson’s disease treated with dopaminergic medication (levodopa and dopamine agonists).
Table 3: Measures of impulsivity after deep brain stimulation or dopaminergic pharmacotherapy in patients with Parkinson’s disease.
Study Outcome measures PD + DBS PD + DA P value
Halbig et al. Barratt impulsiveness
Scale; mean (SD)
“on”
treatment 44.97 (17.29) 36.11 (17.29) 0.04
Czernecki et al.
Stimulus reward
association learning
(number of trials)∗;
mean (SEM)
“on”
treatment 19.2 (3.9) 22.6 (5.6) 0.37 (group)∗∗
“oﬀ”
treatment 23.1 (4.6) 28.8 (4.8)
Reversal∗ (number in
30 trials); mean
(SEM)
“on”
treatment 1.6 (0.2) 1.3 (0.2) 0.48 (group)∗∗
“oﬀ”
treatment 1.3 (0.2) 1.3 (0.2)
Extinction∗ (last
error); mean (SEM)
“on”
treatment 8.1 (1.1) 14.2 (2.5) 0.13 (group)∗∗
“oﬀ”
treatment 10.5 (1.6) 11.8 (1.9)
Gambling task; mean
(SEM)
“on”
treatment 25.4 (10.2) 13.4 (6.9) 0.39 (group)∗∗
“oﬀ”
treatment 19.4 (9.6) 14.2 (6.4)
In all measures (except the Barratt impulsiveness scale and the extinction test), lower scores indicate higher impulsivity.
∗Tasks described in Rolls et al. [17] ∗∗ANOVA results of P-value of group eﬀect (patients on stimulation versus patients on medication)
Abbreviations. PD + DBS: patients with Parkinson’s disease who underwent deep brain stimulation surgery; PD + DA: patients with Parkinson’s disease
treated with dopaminergic medications (levodopa and/or dopamine agonists); “on” treatment: on medication and stimulation (if applicable) on the time of
assessment; “oﬀ”t r e a t m e n t :o ﬀ medication and stimulation.
receiving dopaminergic medication. The methods included
stimulus reward learning with either reversal or extinction
and the gambling task (Table 3). In the stimulus reward
learning procedure, the subjects were faced with a screen
challenging them to learn how to choose the correct pattern
in order to gain maximum points and to progress to further
trials. The task continued to either the reversal phase (testing
sensitivity to reward ﬂexibility) or the extinction phase
(testing the ability to control impulsivity). The gambling
task included making a choice between advantageous (small
gains but smaller loses) and disadvantageous (big gains but
bigger loses) decks. Previous reports by the same authors
using the same tasks identiﬁed that patients with PD
had impaired explicit and implicit reinforcement-associated
learning and “sensitivity to reward” ﬂexibility, compared to
healthy controls [19]. In this study, there was no diﬀerence
between the PD + DBS and PD + DA groups, implying
that although patients with PD may have higher impulsivity
than controls, DBS does not seem to increase it further. In
this study, the preoperative LEDD of the PD + DBS group
did not diﬀer signiﬁcantly from the PD + DA group, whilst
the postoperative mean LEDD of the PD + DBS group was
133.3mg(SEM ±58.7),comparedto982.3mg(SEM ±53.9)
i nt h eP D+D Ag r o u p .
4.CaseReports
We found 9 case reports of 39 patients with PD (33 men
and 6 women) who underwent DBS and developed ICDs
or whose ICDs worsened (n = 22). In other cases (n =
17), patients presented with ICDs that resolved or improved
postoperatively. Although our study selection again involves
publication bias, the case reports will provide detailed
information about the phenomenology of ICDs and the4 Parkinson’s Disease
clinical characteristics of the patients who develop ICDs. The
demographic and clinical characteristics for each patient are
described in Table 4.
Romito et al. [20], Doshi and Bhargava [21], Smeding
et al. [22], Sensi et al. [23], and Lim et al. [24]r e p o r t e d
patients with no preoperative ICDs who developed ICDs
aftersurgery(patients1–7,19,38)(Table 5).Thetimeperiod
between surgery and the development of ICD varied in each
case from immediately after surgery to months later. Most of
the ICDs were transient and resolved within a year of their
development. Lim et al. [24] described a series of patients
with preoperative ICDs that worsened after surgery (patients
20–32); some of these patients developed a wider spectrum
of ICDs after the operation compared to what they had
preoperatively (patients 20–22, 31-32).
Witjas et al. [25], Bandini et al. [26], Ardouin et al.
[27], and Lim et al. [24] described patients with preoperative
ICDs that resolved completely (patients 8–18, 33–35, 39) or
improved signiﬁcantly (patients 36-37) postoperatively. In
all cases, there was a signiﬁcant reduction (reduction to less
than 50% of preoperative dose) in levodopa equivalent daily
dose (LEDD), most commonly in the ﬁrst 3 months after
DBS.MostofthestudiesprovidedtheLEDDforthepatients;
where not explicitly stated, it was calculated as described in
Wenzelburger et al. [28].
Analysis of the ﬁndings of the case reports revealed
that 22 patients (1–7, 19–32, 38) had a “poor outcome”
after DBS, deﬁned as worsening of existing ICDs, new
development of ICDs, or no postoperative improvement
of existing ICDs, and 17 patients (8–18, 33–37, 39) had
a “good outcome” after DBS, deﬁned as improvement of
existing ICDs or resolution of existing ICDs postoperatively
(Table 5). Of the patients with “poor outcome”, 91.1% were
males and 72.7% were older than 55 years, whereas in
the “good outcome” group, only 76.5% were males and
70% of them were older than 55 years. Age information
is not available for all patients in the “good outcome”
group. Previous psychiatric history and postoperative psy-
chiatric conditions were not available for all the patients.
However, it was noted that only 36.4% of patients in the
“good outcome” group had previous behavioral problems,
compared to 42.9% in the “poor outcome” group. The
patients who developed ICDs or whose ICDs worsened after
DBS had a 36.4% chance of developing other psychiatric
conditions. These included depression, manic syndrome,
agitation, anxiety, and psychosis. On the other hand, only
17.7% of the patients in the “good outcome” group devel-
oped other psychiatric conditions postoperatively (depres-
sion).
5. Comments andClinicalImplications
This review paper speciﬁcally examined the literature on
the role of DBS of the subthalamic nucleus on ICDs in
patients with PD. In general, the existing evidence on this
topic is poor, not allowing deﬁnitive conclusions whether
DBS beneﬁts patients with ICDs or whether it actually causes
the development of ICDs.
5.1. Development of ICDs after DBS. Three out of the four
studies described in Tables 1–3 reported the development
of ICDs after DBS surgery. These ﬁndings are in agreement
with22casereportsofpatientswhohadapoorpostoperative
outcomeintermsofICDs.Inmostcases,theICDsdeveloped
despite a postsurgical reduction of dopaminergic medica-
tion. The reasons for the development of ICDs after DBS are
still unknown, and hence a lot of diﬀerent hypothesis have
been proposed.
The ﬁrst hypothesis suggests that STN-DBS increases
impulsivity by stimulating the STN or neighboring ﬁber
tracts, since the STN is interconnected with structures
linked to both associative and limbic circuits within the
basal ganglia. It is proposed that the STN can regulate the
processing of associative and limbic information towards
cortical and subcortical regions, thus inﬂuencing changes
in behavior [29]. This is compatible with studies suggesting
that the STN mediates not only motor but also cognitive
and emotional functions [30]. Even the surgical procedure
itself may have an adverse result on impulsivity, since the
STN is a very compact structure, and it may be diﬃcult to
selectively inﬂuence the motor part of it without damaging
it or its neighboring structures which are associated with
motivational behaviors. This hypothesis was proposed by
Sensi et al., who suggested that a microtraumatic eﬀect of
surgery or a misplacement of the electrodes may be the
reason behind the development of ICDs after DBS [23].
Moreover, minimal changes in the stimulation site can cause
diﬀerent eﬀects; Smeding et al. [22] showed that with the
stimulation of the most dorsal contact of the STN nucleus,
the performance on decision making tasks is worse than with
stimulation of the ventral contact.
Previous reports have shown that in medically treated
patients, higher levodopa dosages are associated with the
development of ICDs [7]. Hence, a possible explanation
for the development of ICDs after DBS is the higher
cumulative exposure to dopaminergic medication due to
longer disease duration and greater disease severity of the
patients who underwent DBS. However, this hypothesis
would not explain why some patients developed ICDs
ex novo after surgery. Further complicating the picture,
postoperative dopaminergic therapy reduction is also likely
to play an important role. As seen in the case reports,
unlike 100% of patients in the “good outcome” group,
only 57.1% of patients in the “poor outcome” group had a
signiﬁcant reduction in their medication. This means that if
preoperative ICDs exist, only a signiﬁcant reduction in the
patient’s medication would improve the patient’s impulsivity
[26]. Moreover, the reduction would presumably be allowed
only if the patient’s motor symptoms improve after surgery
[25]. This explanation may also be supported by the ﬁndings
of the study by Halbig et al., where surgery did not allow
a major reduction in medication postoperatively (with PD
+ DBS and PD + DA having similar LEDD). Hence, in the
probable background of preoperative ICDs and with a high
dose of postoperative dopaminergic medication, the authors
identiﬁedhigherimpulsivityinthePD+DBSgroup.Patients
who remained on dopaminergic medication postoperatively
had a poor outcome in terms of ICDs possibly because DBSParkinson’s Disease 5
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Table 5: Analysis of the outcomes in the case reports presented in Table 4.
Poor outcome Good outcome
Total Number 22 17
Male gender (%) 20/22 (91.1) 13/17 (76.5)
Age ≥ 55 years 16/22 (72.7) 7/10∗ (70)
Post-op medication reduction to less than 50% of pre-op dose 4/7∗ (57.1) 11/11∗ (100)
Psychiatric history 3/7∗ (42.9) 4/11∗ (36.4)
Other psychiatric condition post-op 8/22 (36.4) 3/17 (17.7)
“Poor outcome” is deﬁned as worsening of existing ICDs, development of more ICDs, or no improvement of existing ICDs postoperatively; “good outcome”
is deﬁned as improvement of existing ICDs, disappearance of existing ICDs postoperatively.
∗Information not available for the rest of the patients.
can sensitize the brain to the behavioral eﬀects of dopamine
replacement therapy, especially on the background of high
impulsivity [22].
Finally, a less likely explanation for the appearance
of ICDs after DBS surgery is that the improvement of
motor function in some patients may have facilitated the
full expression of behavioral abnormalities that had been
developed by the use of dopamine replacement therapy
before the operation, as suggested by Houeto et al. [31].
5.2. Improvement of ICDs after DBS. An u m b e ro fc a s e
reports in this paper described patients whose ICDs either
resolved or markedly improved after surgery. However, the
potential role of DBS in the resolution of ICDs is far from
being clear.
Diﬀerent mechanisms have been proposed to explain the
resolutionofICDsafterDBS.Firstofall,itiswellknownthat
dopaminergic stimulation is implicated in impulsive behav-
iors.Moreover,ithasbeenconsistentlyshownthatdopamin-
ergic medications, and in particular dopamine agonists, may
predispose patients with PD to the development of ICDs
[32].ThesigniﬁcantmotorimprovementafterDBSallowsan
important reduction in dopamine replacement therapy and
thus a less pulsatile and nonsuprathreshold stimulation of
the mesolimbic dopamine receptors [27]. Table 4 reveals that
allthepatientsinthe“goodoutcome”grouphadasigniﬁcant
reduction in their medication. Additionally, Czernecki et
al. did not identify higher reward sensitivity in the PD
+ DBS group compared to controls, probably because the
postoperative mean LEDD in the former group was much
lower than in the latter. Moreover, Lim et al. [24] stated
that the ICDs persisted or even worsened in patients who
had to remain on high dopamine replacement therapy due
to poor or moderate motor beneﬁt after DBS. Consistent
to this hypothesis, Ardouin et al. [27] observed that the
progressive improvement of the symptoms of their patient
closely matched the reduction in his medication.
Another possible explanation is that the improvement of
ICDs was due to a direct eﬀect of DBS on the reward seeking
brain circuitry [33]. The inhibition of neuronal circuits
resulting from STN-DBS may aﬀect the direct ascending
dopaminergic and serotoninergic pathways towards the
limbic area which are known to have a role in positive
reinforcing behaviors [25]. Further studies with long-term
followup of patients after DBS using impulsivity measures
and neuroimaging techniques may provide useful informa-
tion on the role of DBS in resolution of ICDs.
5.3. Outcome Predictors. Our results agree with previous
studies suggesting that male sex, younger age of PD onset,
and previous psychiatric history are predisposing factors to
the development of ICDs during the disease course [7, 8].
Most of the patients in the reviewed studies were of male
gender, in agreement with the existing literature that females
are less likely to develop ICDs. However, other reasons may
also explain this; patients with ICDs rarely volunteer and
often deny having these behaviors. Being a female may
exacerbate this eﬀect since most of these conditions (hyper-
sexuality, compulsive eating, and pathological gambling) are
perceived as socially inappropriate and stigmatizing. It was
also noted that being female resulted in better outcome after
surgery; however, the role of confounding factors like age
of disease onset and medication dose should be taken into
account.
Although studies suggested that younger patients may be
more compliant to medication changes and therefore are less
likely to develop ICDs postoperatively [25], the analysis of
the case reports revealed that the number of patients over
55 in the “good outcome” and “poor outcome” groups were
similar.
A number of patients in the “poor outcome” group were
diagnosed with PD early in their life. This is consistent with
previous studies showing that patients with young onset PD
are more likely to present with ICDs [34], ﬁndings which
may reﬂect a confounding eﬀect of prescribing of dopamine
agonists to younger PD patients [35].
Only a few types of ICDs were reported in this paper.
Hypersexuality and pathological gambling are the most
commonly reported and are clearly disabling not only to the
patient but also to his/her relatives. Sometimes, the family
of the patient is more likely to volunteer this information
to the psychiatrist. This is probably the reason why less
distressing ICDs (e.g., compulsive shopping) were reported
less commonly. It is important for the doctor to be aware
of the possibility of development of ICDs in PD patients in
order to provide support to the patient as quickly as possible.
Althoughinformationregardingthepresenceofprevious
psychiatric disorders was not always available, more patients8 Parkinson’s Disease
in the “poor outcome” group had history of psychiatric
disorders compared to those in the “good outcome.” This
suggests a possible association between previous psychiatric
disorders/ history of abuse and ICDs.
Finally, fewer patients in the “good outcome” group suf-
fered from psychiatric comorbidities after surgery compared
to those in the “poor outcome” group. This was expected
as the most common psychiatric disorder was depression,
which would most likely be related to the poor outcome
of the patient as the disease progresses. This stresses the
importance of postoperative followup of these patients in
order to treat any other developing conditions.
5.4. Limitations. At present, there is a clear need for more
conclusive results on the eﬀects of DBS on impulsivity in
patients with PD. The small number of patients in the
original studies did not allow to reach statistical signiﬁcance
and two studies lacked a control group (PD + DA). Addi-
tionally, the studies had diﬀerent follow-up periods in which
ICDs may had been missed. Although similar eligibility
criteria may have made the patients comparable, some of the
exclusion criteria, including cognitive impairment, may have
introduced a bias, since patients with ICDs are more likely to
develop psychiatric comorbidities. Moreover, patients were
lost to follow-up and most likely these patients had worse
outcomes than the rest, further biasing the sample. The
authors adopted diﬀerent methodologies for the analysis
of their results, thus making direct comparison impossible.
Some studies had poor information regarding the patients’
condition before DBS surgery, suggesting that some groups
may had been diﬀerent from the start. Finally, the patients
who had ICDs at the baseline which was not recorded could
have been more likely to choose to undergo DBS, thus
introducing selection bias. To draw more accurate results,
controlled longitudinal studies with baseline impulsivity
measures and long-term follow-up should be conducted on
large numbers of subjects undergoing DBS.
6. Conclusion
Theresultsofthisliteraturereviewshowthatexistingdataare
ambivalent about the role of DBS on impulsivity in patients
withPD.SeveralstudiessupporttheideathatDBSisaneﬀec-
tive indirect treatment of ICDs, whilst other studies report
the worsening or ex novo development of ICDs after surgery.
Various pathophysiological mechanisms, including altered
dopaminergic stimulation, have been proposed to explain
both situations. The selection of patients for DBS should
be extremely careful in order to avoid surgery on patients
who are already predisposed to develop ICDs. Finally, since
the patients are not likely to volunteer their symptoms,
it is important to recognize ICDs both preoperatively
and postoperatively, and to adopt a multidisciplinary team
approach to diagnose and manage the patients accordingly.
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